Related Experiment Video
Updated: May 8, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
[Hypofractionated radiotherapy in prostate cancer].
S Supiot1, G Créhange, I Latorzeff
1Département de radiothérapie, institut de cancérologie de l'Ouest Nantes-Angers, boulevard Jacques-Monod, 44805 Saint-Herblain, France.
Summary
Hypofractionated radiotherapy for prostate cancer offers a shorter treatment duration, reducing patient fatigue and costs. Current data suggest it maintains efficacy and toxicity while potentially improving outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Conventional radiotherapy for localized prostate cancer spans nearly two months, leading to patient fatigue and increased treatment costs.
- Hypofractionation aims to shorten treatment duration while preserving efficacy and toxicity profiles.
- Advanced techniques like image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT) are crucial for hypofractionated protocols.
Purpose of the Study:
- To evaluate the feasibility and outcomes of hypofractionated radiotherapy in localized prostate cancer treatment.
- To assess the impact of hypofractionation on treatment duration, patient fatigue, and healthcare costs.
- To review current clinical data supporting hypofractionation's efficacy and toxicity.
Main Methods:
- Review of single-center series validating "light" hypofractionation (<6 Gy/fraction).
- Analysis of studies on stereotactic irradiation for "severe" hypofractionation (>6 Gy/fraction).
- Evaluation of clinical data regarding mid-term toxicity and biochemical control.
Main Results:
- Hypofractionated radiotherapy, regardless of dose per fraction, shows feasibility.
- Current data indicate no increase in mid-term toxicity compared to conventional fractionation.
- Evidence suggests hypofractionation may improve biochemical control for prostate cancer.
Conclusions:
- Hypofractionated radiotherapy is a feasible and potentially advantageous treatment for localized prostate cancer.
- Further non-inferiority studies are needed to definitively establish its role.
- This approach offers benefits in terms of treatment duration, patient convenience, and cost-effectiveness.
